12:00 AM
Jan 19, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sapacitabine: Phase II started

Cyclacel began an open-label, dose-escalating Phase II trial in about 60 patients. The company licensed exclusive rights to sapacitabine from Daiichi Sankyo in 2003...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >